CN Bio appoints Joseph Parisi as US Director of Sales to support accelerated growth in key OOC market
Cambridge, UK, 30 January 2024: CN Bio, a leading Organ-on-a-Chip (OOC) company that designs and manufactures single- and multi-organ microphysiological systems (MPS), today announced the appointment of Joseph Parisi as US Director of Sales. In his new role, Joe will lead the expansion of the Company’s sales and support activities for the US market to address the growing demand for new alternative methodologies (NAMs) in preclinical drug discovery.
Following several key senior appointments in…
• Wes Streeting, Shadow Health Minister, and Peter Kyle, Shadow Science Minister launch Life Sciences Strategy at Stevenage Bioscience Catalyst (SBC).
• Shadow Ministers take part in roundtable discussion with key industry figures including AstraZeneca, GSK, BioIndustry Association (BIA) and Stevenage Bioscience Catalyst and its high growth companies to hear at first hand the opportunities and challenges facing the sector and the vibrant strength of the UK’s life science ecosystem.
Wes Streeting, Shadow Health Minister, and Peter Kyle, Shadow Science Minister, today launched Labour’s Life…
Source Genomics Expands Sequencing Portfolio with First UK Commercial Service on the Element Biosciences AVITI™ System
Cambridge, UK, 31 January 2024: Source Genomics, a part of the Source BioScience Group, today announced their genomic laboratory expansion by adding an Element Biosciences AVITI™ System to its fleet of sequencers.
As the demand for genomic sequencing increases in the UK, Source Genomics is expanding its offering to meet the escalating needs of the life science research market. The incorporation of Element Biosciences AVITI™ System is set to transform the landscape of genomic…
Pioneer Group, a company combining laboratory development and operation with venture building, has teamed up with CPI, the independent deep tech innovation organisation, to launch a Golden Ticket programme for innovations in planetary health.
The 2024 Golden Ticket Programme is open to hydrogen and climate technology companies that are innovating solutions to some of the biggest challenges we face, with funding for the initiative coming from the Hydrogen Innovation Initiative (HII) – a trusted group of organisations working with industry, government, and academia to create an investible,…
This week the University of Cambridge announce the appointment of Dr Diarmuid O'Brien, current Chief Executive of Cambridge Enterprise, as their new Pro-Vice-Chancellor of Innovation.
Click here to read the full story.
London, UK - Award-winning science communications agency First Create The Media is delighted to announce the appointment of Dr Sarah Hazell as its new Chief Executive Officer.
Founded in 2018 by renowned science writer and broadcaster Dr Kat Arney, First Create The Media has quickly become a prominent player in the life sciences sector. The agency brings together a team of experts with decades of experience to provide strategic communications consultancy and high quality written, audio and video content for innovative companies and the ecosystem that supports them.
First Create The Media…
London, 24 January 2024 – Kadans Science Partner (“Kadans”) has received planning approval from Cambridge City Council for the development of a new, purpose-built laboratory and office building at Merlin Place, Cambridge, a new Gateway Building for the Cambridge North Cluster.
The six-storey 139,000 sq ft building allows for full flexibility from a single to multi tenant split. The design includes south-facing balconies benefiting from unrivalled views to the historic city centre along with significant communal space and a much-needed additional public café to the Cambridge North Cluster with…
Arecor Therapeutics plc
(“Arecor” or the “Company”)
ARECOR ANNOUNCES UPDATE ON INBRX-101
- Sanofi to acquire Inhibrx’s AATD therapy INBRX-101, which incorporates a novel formulation developed under a license agreement using Arecor’s Arestat™ technology, for up to $2.2 billion
- Terms of Arecor’s license agreement are unchanged. Arecor remains entitled to further payments on achievement of certain development, regulatory and commercial milestones along with annual Technology Access Fees post commercialisation
Cambridge, UK, 23 January 2024: Arecor Therapeutics plc (AIM: AREC), the…
Arecor Therapeutics plc
(“Arecor” or the “Group”)
ARECOR GRANTED KEY EUROPEAN PATENT EXTENDING PROTECTION FOR INSULIN PRODUCTS, AT278 AND AT247
Cambridge, UK, 18 January 2024: Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical group advancing today’s therapies to enable healthier lives, is pleased to announce that the European Patent Office has granted a patent (EP3618840) protecting novel formulations of the Group’s proprietary insulin products, AT278 and AT247. The European patent adds to a comprehensive global intellectual property (IP) portfolio protecting the Group’s novel…
Apply now to participate in the next Pioneer Accelerator Programme designed to help businesses launch, grow and scale.
Available programmes include:
Pioneer Group Accelerator Programme, Ireland
Health Innovation East Midlands NHS Programme
Pioneer Group Accelerator Programme, England & Wales
Pioneer Group Accelerator Programme, Scotland
For more information, please visit: https://thepioneergroup.com/accelerator-programme/